Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported Total Revenue of $3.71 billion for fiscal year 2025.
ALNYLAM PHARMACEUTICALS, INC. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $3.71B | +65.2% |
| 2024 | $2.25B | +23.0% |
| 2023 | $1.83B | +76.2% |
| 2022 | $1.04B | +22.9% |
| 2021 | $844.29M | +71.3% |
| 2020 | $492.85M | +124.3% |
| 2019 | $219.75M | +193.4% |
| 2018 | $74.91M | +2483.0% |
| 2017 | $2.90M | -93.9% |
| 2016 | $47.16M | -52.9% |
| 2010 | $100.04M | -0.5% |
| 2009 | $100.53M | +4.5% |
| 2008 | $96.16M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.25B | +149.3% | +61.4% |
| June 30, 2025 | $773.69M | +17.3% | +30.2% |
| March 31, 2025 | $594.19M | +20.2% | +18.6% |
| September 30, 2024 | $500.92M | -33.3% | -24.1% |
| June 30, 2024 | $659.83M | +107.0% | +33.5% |
| March 31, 2024 | $494.33M | +54.8% | -34.1% |
| September 30, 2023 | $750.53M | +184.0% | +135.5% |
| June 30, 2023 | $318.75M | +41.8% | -0.2% |
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +65.2% in Total Revenue compared to the prior fiscal year.
- Over the 2008–2025 period, ALNYLAM PHARMACEUTICALS, INC.’s total revenue has grown by 3762.1% (from $96.16 million to $3.71 billion).
- The most recent figure is from ALNYLAM PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: